Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia

14 augusti 2026 uppdaterad av: The Methodist Hospital Research Institute

Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation

This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros Robotic System. Men with BPH and prostate volumes between 50 and 180 mL will be randomly assigned to one of the two procedures. The study will measure changes in prostate volume, PSA, urinary flow, and bladder emptying at 12 months, along with safety, sexual function, continence, and healthcare utilization outcomes, which will be followed for up to 5 years after surgery.

Studieöversikt

Detaljerad beskrivning

This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.

The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).

Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.

Studietyp

Interventionell

Inskrivning (Beräknad)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Male, age 50-80 years
  2. International Prostate Symptom Score (IPSS) ≥ 12
  3. Prostate size (TRUS): 50-180 mL
  4. Diagnosis of LUTS due to BPH
  5. Uroflow Qmax ≤ 15 mL/sec
  6. Mentally capable, able to comply with study procedures, written informed consent provided
  7. Able to follow study instructions and complete all required visits

Exclusion Criteria:

  1. BMI ≥ 42
  2. History of prostate cancer
  3. Suspected or history of bladder cancer
  4. Active or untreated bladder stones at screening
  5. Indwelling catheter for more than 3 months before baseline
  6. Active urinary tract infection
  7. History of urethral stricture or bladder neck stenosis
  8. Damage to the external urethral sphincter
  9. Previous prostate surgery or lower urinary tract surgery
  10. Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
  11. Contraindications to general and spinal anesthesia
  12. Any condition that could interfere with study participation or outcomes, per investigator judgment
  13. Lacks legal or mental capacity to consent
  14. Simultaneous participation in another therapeutic urological trial
  15. Known or persistent abuse of medication, drugs, or alcohol

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
Aktiv komparator: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Prostate Volume
Tidsram: Baseline and 12 months post-intervention
Measured via transrectal ultrasound (TRUS); change from baseline.
Baseline and 12 months post-intervention
Change in Prostate-Specific Antigen (PSA)
Tidsram: Baseline and 12 months post-intervention
Serum PSA level; change from baseline.
Baseline and 12 months post-intervention
Change in Urinary Flow Rate (Qmax)
Tidsram: Baseline and 12 months post-intervention
Peak urinary flow rate via uroflowmetry; change from baseline.
Baseline and 12 months post-intervention
Change in Post-Void Residual Volume (PVR)
Tidsram: Baseline and 12 months post-intervention
Bladder scan-measured PVR; change from baseline.
Baseline and 12 months post-intervention

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence and Severity of Adverse Events
Tidsram: From patient hospital discharge through 3 and 12 months post-surgery
Adverse events graded by the Clavien-Dindo classification system.
From patient hospital discharge through 3 and 12 months post-surgery
Operative Time
Tidsram: Day (duration) of surgical procedure
Total procedure time, start to finish.
Day (duration) of surgical procedure
Hemostasis Time
Tidsram: Day (duration) of surgical procedure
Time required to achieve hemostasis intraoperatively.
Day (duration) of surgical procedure
Perioperative Change in Hemoglobin
Tidsram: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Hemoglobin level change from baseline to immediate postoperative measurement.
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
Time to Catheter-Free Status
Tidsram: From surgery day until catheter removal
Duration from end of surgery to catheter removal.
From surgery day until catheter removal
Length of Hospital Stay / Discharge Time
Tidsram: Day of surgical procedure through hospital discharge
Time from surgery to hospital discharge.
Day of surgical procedure through hospital discharge
Change in IPSS/QoL Score
Tidsram: Baseline, 3, 6, and 12 months post-surgery
International Prostate Symptom Score / Quality of Life index.
Baseline, 3, 6, and 12 months post-surgery
Change in SHIM Score
Tidsram: Baseline, 3, 6, and 12 months post-surgery
Sexual Health Inventory for Men.
Baseline, 3, 6, and 12 months post-surgery
Change in MSHQ-EjD Score
Tidsram: Baseline, 3, 6, and 12 months post-surgery
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
Baseline, 3, 6, and 12 months post-surgery
Change in Incontinence Outcomes
Tidsram: Baseline, 3, 6, and 12 months post-surgery
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
Baseline, 3, 6, and 12 months post-surgery
Long-Term Durability of Functional Improvements
Tidsram: 24, 36, 48, and 60 months post-intervention
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
24, 36, 48, and 60 months post-intervention
Post-Operative Medication Use
Tidsram: Through 60 months post-intervention
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
Through 60 months post-intervention
Reintervention Rate
Tidsram: Through 60 months post-intervention
Repeat procedures or additional therapies for BPH/LUTS.
Through 60 months post-intervention
Unplanned Healthcare Encounters
Tidsram: Through 60 months post-intervention
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
Through 60 months post-intervention
Incidence of Urethral Stricture Requiring Intervention
Tidsram: Through 60 months post-intervention
New urethral stricture or bladder neck stenosis requiring treatment.
Through 60 months post-intervention
Unanticipated Advanced Diagnostics
Tidsram: Through 60 months post-intervention
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
Through 60 months post-intervention

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

3 augusti 2026

Primärt slutförande (Beräknad)

3 augusti 2029

Avslutad studie (Beräknad)

3 augusti 2033

Studieregistreringsdatum

Först inskickad

9 juli 2026

Först inskickad som uppfyllde QC-kriterierna

14 augusti 2026

Första postat (Faktisk)

19 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera